Journal article · 2017 · Open access

Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells

Malika R. Hale, Taylor D. Mesojednik, Guillermo S. Romano Ibarra, Jaya Sahni, Alison Bernard, Karen Sommer, Andrew M. Scharenberg, David J. Rawlings, Thor A. Wagner

Molecular Therapy, 25(3), 570–579 · Published 28 January 2017 · DOI 10.1016/j.ymthe.2016.12.023

Open PDFView at the publisherCite this paper

In brief

“Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells” is a 2017 journal article by Malika R. Hale and 8 co-authors, published in Molecular Therapy. OpenAlex counts 181 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Therapy.

Citations
181
Most cited in
2023 (26)
Field-weighted impact
9.42
References
73
Authors
9

Abstract

The treatment or cure of HIV infection by cell and gene therapy has been a goal for decades. Recent advances in both gene editing and chimeric antigen receptor (CAR) technology have created new therapeutic possibilities for a variety of diseases. Broadly neutralizing monoclonal antibodies (bNAbs) with specificity for the HIV envelope glycoprotein provide a promising means of targeting HIV-infected cells. Here we show that primary human T cells engineered to express anti-HIV CARs based on bNAbs (HIVCAR) show specific activation and killing of HIV-infected versus uninfected cells in the absence of HIV replication. We also show that homology-directed recombination of the HIVCAR gene expression cassette into the CCR5 locus enhances suppression of replicating virus compared with HIVCAR expression alone. This work demonstrates that HIV immunotherapy utilizing potent bNAb-based single-chain variable fragments fused to second-generation CAR signaling domains, delivered directly into the CCR5 locus of T cells by homology-directed gene editing, is feasible and effective. This strategy has the potential to target HIV-infected cells in HIV-infected individuals, which might help in the effort to cure HIV.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hale, M. R., Mesojednik, T. D., Ibarra, G. S. R., Sahni, J., Bernard, A., Sommer, K., Scharenberg, A. M., Rawlings, D. J., & Wagner, T. A. (2017). Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. Molecular Therapy, 25(3), 570–579. https://doi.org/10.1016/j.ymthe.2016.12.023

MLA 9

Hale, Malika R., et al. “Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.” Molecular Therapy, vol. 25, no. 3, 2017, pp. 570–579. https://doi.org/10.1016/j.ymthe.2016.12.023.

Chicago

Hale, Malika R., Taylor D. Mesojednik, Guillermo S. Romano Ibarra, Jaya Sahni, Alison Bernard, Karen Sommer, Andrew M. Scharenberg, David J. Rawlings, and Thor A. Wagner. 2017. “Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.” Molecular Therapy 25 (3): 570–579. https://doi.org/10.1016/j.ymthe.2016.12.023.

Harvard

Hale, M. R. et al. (2017) ‘Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells’, Molecular Therapy, 25(3), pp. 570–579. doi:10.1016/j.ymthe.2016.12.023.

IEEE

M. R. Hale et al., “Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells,” Molecular Therapy, vol. 25, no. 3, pp. 570–579, 2017, doi: 10.1016/j.ymthe.2016.12.023.

BibTeX

@article{hale2017engineering,
  title     = {{Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells}},
  author    = {Hale, Malika R. and Mesojednik, Taylor D. and Ibarra, Guillermo S. Romano and Sahni, Jaya and Bernard, Alison and Sommer, Karen and Scharenberg, Andrew M. and Rawlings, David J. and Wagner, Thor A.},
  journal   = {Molecular Therapy},
  year      = {2017},
  volume    = {25},
  number    = {3},
  pages     = {570--579},
  doi       = {10.1016/j.ymthe.2016.12.023},
  url       = {https://doi.org/10.1016/j.ymthe.2016.12.023}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171111
20181616
20192222
20202525
20211818
20222323
20232626
20241919
20251010
20261010

Its field-weighted citation impact is 9.42: it has been cited 9.42 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • HIV
  • chimeric antigen receptor T cells
  • broadly neutralizing monoclonal antibodies
  • envelope glycoprotein
  • homology-directed recombination
  • genome editing
  • HIV cure
  • HIV immunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Hale, M. R., Mesojednik, T. D., Ibarra, G. S. R., Sahni, J., Bernard, A., Sommer, K., Scharenberg, A. M., Rawlings, D. J., & Wagner, T. A. (2017). Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. Molecular Therapy, 25(3), 570–579. https://doi.org/10.1016/j.ymthe.2016.12.023

How many times has this paper been cited?

181 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Malika R. Hale, Taylor D. Mesojednik, Guillermo S. Romano Ibarra, Jaya Sahni, Alison Bernard, Karen Sommer, Andrew M. Scharenberg, David J. Rawlings, Thor A. Wagner.

What is the DOI of this paper?

10.1016/j.ymthe.2016.12.023, permanently at https://doi.org/10.1016/j.ymthe.2016.12.023. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.